PUBLICATIONS

Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors

Quinlan Sievers, Hao Lu, Allison Cool, Stefan Gajewski, Tim Kong, Mark A. Noviski, Sarah Whelan, Yuhan Wang, Lizbeth Mendoza Navarrete, Xiaoli Mi, Emel Ficici, Ratul Mukerji, James N. Iuliano, Jordan Ye, Mateo Sanchez Garcia De Los Rios, Hugo Bousquet, May Tan, Nivetha Brathaban, Nell Narasappa, Ya-Wen Lu, Jennifer Elechko, Maxim I. Maron, Christopher B. Phelps, Jahan Rahman, Ryan Q. Notti, Samantha Sekeres, Erica N. Lamkin, Eduardo Bravo, Alvaro Alencar, Mark D. Ewalt, Prioty Islam, Anthony R. Mato, Lindsey Roeker, Shruti Bhatt, Justin Taylor, Meghan C. Thompson, Gwenn M. Hansen, Omar Abdel-Wahab

Cancer Discovery July/22/2026, https://doi.org/10.1158/2159-8290.CD-26-0251

TP53 mutations drive therapy resistance through post-mitochondrial caspase blockade

Ahmed M. Mamdouh, Fizza Iftikhar, Elyse A. Olesinski, Fang Qi Lim, Shaista Jasdanwala, Yuhan Wang, Yang Mi, Nicole Si En Lin, Daniel Tan En Liang, Md Al Nayem Chowdhury, Nishtha Chitkara, Leah Hogdal, Coleman R. Lindsley, Anthony Letai, Koji Itahana, Shruti Bhatt

Cell Death & Disease July/28/2026, https://www.nature.com/articles/s41419-026-09087-0

Non-reducing PAGE for detection of oligomerized pore-forming proteins in regulated cell death

Methods in Cell Biology

Aarthi Nivasini Mahesh, Ahmed M. Mamdouh, and Shruti Bhatt

Methods in Cell Biology 2026, https://doi.org/10.1016/bs.mcb.2026.05.005

Pandora’s Box of AML: How TP53 Mutations Defy Therapy and Hint at New Hope

Biomedicines: MDPI

Elyse A. Olesinski and Shruti Bhatt

Biomedicines 2025, 13, 3007, https://doi.org/10.3390/biomedicines13123007

Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)

bioRxiv

Chuqi Wang, Yuhan Wang, Camillo Benetti, Xiao Xian Lin, Enes Dasdemir, Petra Hyroššová, Jordan Yong Ming Tan, Edward Ayoub, Karanpreet Singh Bhatia, Fang Qi Lim, Yun Li, Zihui Zhao, Ahmed M. Mamdouh, Shir Ying Lee, Jakub Rohlena, Chad V. Pecot, Michael Andreeff, Katerina Rohlenova, Hussein A. Abbas, Shruti Bhatt
bioRxiv 2025.11.01.686055; doi: https://doi.org/10.1101/2025.11.01.686055

TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade

bioRxiv

Ahmed M. Mamdouh, Elyse A. Olesinski, Fang Qi Lim, Shaista Jasdanwala, Yang Mi, Nicole Si En Lin, Daniel Tan En Liang, Nishtha Chitkara, Leah Hogdal, R. Coleman Lindsley, Anthony Letai, Koji Itahana, Shruti Bhatt

bioRxiv, https://doi.org/10.1101/2025.08.28.672283

BIRC5 Dependency Defines a Targetable Vulnerability in TP53 Mutant Acute Myeloid Leukemia

bioRxiv

Ahmed M. Mamdouh, Fang Qi Lim, Yang Mi, Elyse A. Olesinski, Shaista

Jasdanwala, Xiao Xian Lin, Edward Ayoub, Jordan Yong Ming Tan, Karanpreet Singh

Bhatia, Yichen Wang, Shradha Garnaik, Kunal Tomar, Valeriia Sapozhnikova Cheryl

Gek Teng Chan, Chuqi Wang, Aarthi Nivasini Mahesh, Philipp Mertins, Brandon D.

Brown, Torsten Haferlach, Melissa Ooi, Camille Lobry, Alexandre Puissant, Justin Taylor, Hussein Abbas, Steven M. Kornblau, Peter G. Miller, Sanjukta Das, Jan Krönke, Koji Itahana, Michael Andreeff, Shruti Bhatt

bioRxiv https://doi.org/10.1101/2025.05.17.654633

Navigating life as an early career researcher

Trends in Cancer

Bhatt S, Chhabra Y, Cohen M, Färkkilä A, Goel S, Li G, Romero-Córdoba S

2025 Apr 1;11(4):261-6

Protocol for the simultaneous activation and lentiviral transduction of primary human T cells with artificial T cell receptors

STAR Protocols

Tan JYM, Tan JC, Wang C, Wu L, Gascoigne NR, Bhatt S.

2025 Mar 21;6(1):103685. https://doi.org/10.1016/j.xpro.2025.103685

Pediatric AML: state of the Art and Future Directions

Pediatric Hematology and Oncology

Iyer P.

2025 Mar; 42(2):126-145. doi: 10.1080/08880018.2025.2453861. Epub 2025 Jan 31. PMID: 39889807.

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Blood

Nair R, Vu A, Freer AK, Bhatia KS, Wang D, Savani MR, Matulis SM, Lonial S, Jaye DL, Boise LH, Seo SY, Corson TW, Nooka AK, Bhatt S, McBrayer SK, Gupta VA, Hu X, Barwick BG, Reddi AR, Shanmugam M.

2024 Dec 18. https://doi.org/10.1182/blood.2024025690. Online ahead of print. PMID: 39693611

Decoding Acute Myeloid Leukemia: A Clinician’s Guide to Functional Profiling

Diagnostics

Iyer P, Jasdanwala SS, Wang Y, Bhatia K, Bhatt S

2024 Nov 14. https://doi.org/10.3390/diagnostics14222560

The BIM Deletion Polymorphism Potentiates the Survival of Leukemia Stem and Progenitor Cells and Impairs Response to Targeted Therapies

Leukemia

Yu M, Nah GSS, Krishnan V, Sulaimi FNB, Ng KP, Wang C, Bhatt S, Chuah C, Bergstrom DE, Ong ST. 2024 Oct 22. https://doi.org/10.1038/s41375-024-02418-0

Mitochondria and Acute Leukemia: A Clinician's Perspective

International Journal of Molecular Sciences

Iyer P, Jasdanwala SS, Bhatia K, Bhatt S

2024 Sep 7; 25(17):9704. doi: https://doi.org/10.3390/ijms25179704

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications

Cancers

Wang CQ, Tan JYM, Chitkara N, Bhatt S.

2024 Sep 3; 16(17):3069. doi:https://doi.org/10.3390/cancers16173069

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition

Leukemia

Chaudhry S, Beckedorff F, Jasdanwala SS, Totiger TM, Affer M, Lawal AE, Montoya S, Tamiro F, Tonini O, Chirino A, Adams A, Sondhi AK, Noudali S, Cornista AM, Nicholls M, Afaghani J, Robayo P, Bilbao D, Nimer SD, Rodríguez JA, Bhatt S, Wang E, Taylor J.

2024 Jul 13. doi: https://doi.org/10.1038/s41375-024-02328-1

Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches

Frontiers in Oncology

Bhatia, KS; Sandhu, V; Wong, MH; Iyer, P; Bhatt, S

February 2024 DOI: https://doi.org/10.3389/fonc.2024.1275251

Acquired multi-drug resistance in AML is caused by low apoptotic priming in relapsed myeloblasts

Blood Cancer Discovery

Olesinski, EA; Bhatia, KS; Wang, CQ; Pioso, MS; Lin, XX; Mamdouh, AM; Ng, SX; Sandhu, V; Jasdanwala, SS; Yilma, B; Bohl, S; Ryan, JA; Malani, D; Luskin, MR;, Kallioniemi, O; Porkka, K; Adamia, S; Chng, WJ; Osato, M; Weinstock, DM; Garcia, JS; Letai, Anthony; Bhatt, S

2024 Feb 19 DOI: https://doi.org/10.1158/2643-3230.BCD-24-0001

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Blood

Miller, PG; Sperling, AS; Mayerhofer C; McConkey, ME; Ellegast, JM; Da Silva, C; Cohen, DM, Wang, CQ; Sharda, A; Yan, N; Saha, S; Schluter, C; Schechter, I; Słabicki, M' Sandoval, B; Khan, J; Boettcher, S; Gibson, CJ; Scadden, DT; Stegmaier, K; Bhatt, S, Lindsley, RC; Ebert, BL

2023 Dec 14;142(24):2079-2091 DOI: https://doi.org/10.1182/blood.2023020331

DFNA5-mediated pyroptosis is a driver for venetoclax and azacytidine synergy in myeloid leukemia

bioRxiv

Mahesh, AN, Lai, JXY, Tng, MJL, Lin, WL, Wan, JC, Yoon, JH, Chen, KW, Bhatt S

2023 Nov 18 https://doi.org/10.1101/2023.11.17.567421

Cytochrome P450

Encyclopedia of Toxicology (Fourth Edition)

Mahesh AN, Bhatia KS, Bhatt S.

2023 Nov 1; Vol. 3 Pg 449-456

Cell Cycle

Encyclopedia of Toxicology (Fourth Edition)

Mahesh AN, Bhatia KS, Bhatt S.

2023 Nov 1; Vol. 2 Pg 667-674

Apoptosis, necrosis, and other forms of cell death

Encyclopedia of Toxicology (Fourth Edition)

Mahesh AN, Lim NSE, Wong MH, Ray SD, Bhatt S.

2023 Nov 1; Vol. 1 Pg 749-759 https://touroscholar.touro.edu/tcopny_pubs/438

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Blood Advances

Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, Jain N, Garcia JS, Wong GC, Ooi M, Letai A, Konopleva M, Bhatt S.

2023 Jun 27;7(12):2917-2923. https://doi.org/10.1182/bloodadvances.2022007728

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response

Leukemia

Jutzi JS, Marneth AE, Jiménez-Santos MJ, Hem J, Guerra-Moreno A, Rolles B, Bhatt S, Myers SA, Carr SA, Hong Y, Pozdnyakova O, van Galen P, Al-Shahrour F, Nam AS, Mullally A.

2022 Dec;37(2):359-369. https://doi.org/10.1038/s41375-022-01781-0

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.

Leukemia

Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso MS, Abiatari I, Letai A, Dorfman DM, Hideshima T, Anderson KC.
2022 Apr;36(4):1088-1101 https://doi.org/10.1038/s41375-021-01475-z

Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma,

Blood

Adamia S, Chyra Z, O'Keefe M, Bhatt S, Wen K, Fell G, Tai YT, Letai A, Abiatari I, Dorfman D, Hideshima T, Anderson K.

2021 November;138, Supplement 1, 2021, Page 2688.

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse model

Star Protocols

Olesinski EA, Bhatt S.

2021 May 12;2(2):100461 10.1016/j.xpro.2021.100461

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

Cancer Cell

Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint AJ, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A.

2020 Dec 14;38(6):872-890.e6

Commentary: Mitochondria in Their Prime Drive Venetoclax Response in Acute Myeloid Leukemia, Cell Press, Mette C. Kriegbaum et Kristen Wennerberg 2020 10.1016/j.ccell.2020.10.018

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.

American Journal of Hematology

Garcia JS*, Bhatt S*, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A.

2020 Mar;95(3):245-250. https://doi.org/10.1002/ajh.25692

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Blood

Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL.

2019 Jul 11;134(2):160-170. https://doi.org/10.1182/blood.2019000789

Statins enhance efficacy of venetoclax in blood cancers.

Science Translational Medicine

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

2018 Jun 13;10(445). 10.1126/scitranslmed.aaq1240

Inhibition of USP10 induces degradation of oncogenic FLT3.

Nature Chemical Biology

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ.

2017 Dec;13(12):1207-1215. DOI: 10.1038/nchembio.2486

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.

Blood.

Bhatt S*, Parvin S*, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS.

2017 Apr 20;129(16):2246-2256. https://doi.org/10.1182/blood-2016-09-738211

Interleukin 21 - its potential role in the therapy of B-cell lymphomas.

Leukemia & Lymphoma

Bhatt S, Sarosiek KA, Lossos IS.

2017 Jan;58(1):17-29. https://doi.org/10.1080/10428194.2016.1201568

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.

Blood

Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, Advani R, Tan L, Zhang J, Choi HG, Tibshirani R, Buhrlage SJ, Gratzinger D, Verdun R, Gray NS, Lossos IS.

2016 Jul 14;128(2):239-48. https://doi.org/10.1182/blood-2016-02-696856

miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.

Blood

Kozloski GA, Jiang X, Bhatt S, Ruiz J, Vega F, Shaknovich R, Melnick A, Lossos IS.

2016 Jun 9;127(23):2856-66. https://doi.org/10.1182/blood-2015-11-680462

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Blood

Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS.

2015 Sep 24;126(13):1555-64.

Commentary: Anti-CD20-IL-21 Fusokine: The Tail Wags the Dog, Stephen M. Ansell, Blood, April 2017 Volume 129, Number 16
- Read More
Commentary: A Two-Pronged Attack Against Mantle Cell Lymphoma, Christian Steidl, Blood, September 2015 Volume 126, Number 13
- Read More

Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors.

Leukemia

Zhu D*, Bhatt S*, Lu X, Guo F, Veelken H, Hsu DK, Liu FT, Alvarez Cubela S, Kunkalla K, Vega F, Chapman-Fredricks JR, Lossos IS.

2015 Jul;29(7):1587-99. https://doi.org/10.1038/leu.2015.39

CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Blood

Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, Mesri EA, Lossos IS.

2013 Aug 15;122(7):1233-42. https://doi.org/10.1182/blood-2013-01-481713

Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

Journal of Clinical Investigation

Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS, Ramos JC.

2013 Jun;123(6):2616-28. https://doi.org/10.1172/JCI64503

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Proceedings of the National Academy of Sciences of the United States of America

Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS.

2010 Jul 20;107(29):13069-74. DOI: https://doi.org/10.1073/pnas.1002985107